
Pipeline
Our pipeline derives from our in-house RDC (Radionuclide Drug Conjugate) discovery capabilities and is comprised of highly differentiated programs.
Cancer Indications
Isotope
Discovery
Preclinical
FIH
Phase I
Phase II
PSMA
Prostate Cancer
SSTR2×CCK2R
NETs
SCLC
MTC
NTSR-1
GI Cancers
SCCHN
GCC
Colorectal
Gastric
Pancreatic
10+ Early Programs
Cancers
PSMA
-
Cancer Indications
Prostate Cancer
-
Isotope
-
- Discovery
- Preclinical
- FIH
- Phase I
- Phase II
SSTR2×CCK2R
-
Cancer Indications
NETs
SCLC
MTC
-
Isotope
-
- Discovery
- Preclinical
- FIH
- Phase I
- Phase II
NTSR-1
-
Cancer Indications
GI Cancers
SCCHN
-
Isotope
-
- Discovery
- Preclinical
- FIH
- Phase I
- Phase II
GCC
-
Cancer Indications
Colorectal
Gastric
Pancreatic
-
Isotope
-
- Discovery
- Preclinical
- FIH
- Phase I
- Phase II
10+ Early Programs
-
Cancer Indications
Cancers
-
Isotope
-
- Discovery
- Preclinical
- FIH
- Phase I
- Phase II
225Ac=Actinium 225
177Lu=Lutetium 177